October 19, 2026

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

Reminder, the following clinical trials are open to enrollment. Please continue to review your patient population and discuss enrollment opportunities with your clinical teams. All protocol related documents are posted on CTSU.

NRG-GU015 (ARCHER) is recruiting patients with invasive muscle bladder cancer who would like to avoid surgery to remove the bladder. 

FORM UPDATES

CANCER PREVENTION & CONTROL

NRG-CC009: The Non-protocol Radiation form and Non-protocol Surgery form have been updated with additional fields. Please use version date, October 12, 2026.

OTHER PROTOCOL NOTICES

BIOSPECIMEN BANK

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More



BREAST

NRG-BR009 (OFSET): Study webinars scheduled for November 5, 10, and 19. Please see the memorandum, dated October 19, 2026, for more information and how to register (posted on CTSU)   

CANCER CONTROL & PREVENTION

NRG-CC005 (FORTE): Clinical research professionals can sign up for NRG Oncology Weekly Broadcasts to receive monthly FORTE Fridays updates directly to your inbox (click here). 

GASTROINTESTINAL

NRG-GI008 (CIRCULATE-North America): Please see the memorandum, dated August 31, 2026, (posted on CTSU) for Important Information regarding the Natera Investigator Portal for Kit Ordering.

GENITOURINARY

NRG-GU015: Attn sites in Canada – Amendments 1 & 2 have been approved by Health Canada. The NOL and forms are posted on CTSU. Please submit the CTSI and protocol signature page to CTSU.

GYNECOLOGIC

NRG-GY031: Please note there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

NRG-GY035: Please note, the WB03 Streck whole blood sample should be collected “at progression or end of maintenance, prior to the patient going off study.” This will be clarified in an upcoming amendment.

NRG-GY037: An amendment is under review by CTEP that will allow for 15 unstained sections (5um, charged) to be submitted in lieu of a block if absolutely necessary. While the amendment is awaiting CTEP review and approval, sites may submit unstained slides in lieu of a block without emailing the study team for an exception. Please note, submission of tumor blocks is strongly recommended.

Additionally, there is an error in the informed consent. The informed consent should read “carboplatin” for the induction sentence but instead reads “cisplatin”. Throughout the protocol and other parts of the informed consent there is mention of carboplatin induction. This will be corrected with the next amendment.

NRG-GY038: Please note a clarification regarding urinalysis monitoring on NRG-GY038. As stated in the study calendar footnote and Section 4.2, urinalysis is to be collected every other cycle during both the treatment and bevacizumab maintenance phases for patients on both Arms. The corresponding box on the Table in Section 4.2 for the maintenance phase was inadvertently not marked. Sites should continue to collect urinalysis every other cycle throughout bevacizumab maintenance, consistent with standard renal/proteinuria monitoring for bevacizumab.

This discrepancy will be formally corrected in an upcoming protocol amendment. No action beyond continued every-other-cycle urinalysis collection during maintenance is required at this time.

HEAD & NECK

NRG-HN006: Attn sites in Canada – Amendment 3 has been approved by Health Canada. The NOL and forms are posted on CTSU. Please submit the CTSI and protocol signature page to CTSU.

VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-CC015, NRG-GI011, NRG-GI012, NRG-GU015, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for November 11, 2026

SUMMARY OF RESULTS FOR PATIENTS

NRG/GOG-0278 and NRG/RTOG-1114: A summary of research results is available on the NRG Patient Study Materials Webpage. Sites, please share the summary of research results with study participants.

Investigator Brochure (IB) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. NRG Oncology Currents Newsletter

The October NRG Currents edition is now available! In this issue, Breast Cancer Awareness Month featuring a study update on NRG-BR009 OFSET, PSC news, information about TrialMatch, FORTE study updates, our monthly Advocate Angle article & more! Check it out here.

2. NCORP Pilot Grant Call for Letter of Intent (LOI) – Due Date, October 30, 2026

NRG NCORP is soliciting LOIs in preparation for the next NCORP pilot grant RFA.

• Anyone interested in applying must submit a Letter of Intent (LOI) by October 30, 2026. Click here to download the form
• The request for funding application (RFA) for NCORP pilot projects will be released in Spring 2027; however, interested applicants must submit a LOI.
• NCORP committee chairs will review LOIs and select those best aligned with committee goals, NCORP priorities and feasible.
• Selected investigators will be notified and invited to attend a workshop at the NRG Winter Meeting in Las Vegas, NV, January 28-30, 2027
• Informational slides are available here.

3. NRG Oncology Health Care Access Fellowship Call for Applications – Due Date, October 23, 2026

The NRG Oncology Health Care Access Fellowship Program trains selected early-stage investigators in the NRG Oncology system by means of a structured mentorship experience, with particular emphasis given to the recruitment of researchers with a passion for improving health care access. Our vision is to have at least one scholar for every disease site we study.

Applications for the 2027-2028 fellowship will be due October 23, 2026. Please submit the application, letter of support, biosketch and relevant materials to Fellowships@NRGOncology.org. Additional information about the program is posted on the NRG Oncology website.

4. REGISTER TODAY: Therapeutic Radiopharmaceuticals - Where Specialties Combine to Bring Novel Cancer Interventions

Join us for the next Radiation Oncology Webinar Series on October 21, 2026, from 4:00-6:00 PM ET. This session is titled "Therapeutic Radiopharmaceuticals - Where Specialties Combine to Bring Novel Cancer Interventions" and will feature presentations on clinical RPT dosimetry, PSMA theranostics, and imaging in theranostics. There will be an opportunity for attendees to ask our speakers questions regarding the topics discussed. This activity has been approved for AMA PRA Category 1 Credit™. Register here to attend

5. REGISTER: NRG-GI011 and NRG-GI012 Webinar

NRG Oncology will be hosting a webinar on the NRG-GI011 “LAP100” study of dose escalated radiation in locally advanced pancreas cancer patients and the NRG-GI012 “HELIO-RT” study of IO-based systemic treatment with or without liver SBRT in hepatocellular cancer with macrovascular invasion. This session will be held on Monday, November 2, 2026 from 2:00-3:00PM ET. Register here to attend.

6. NRG Oncology Committee Openings

NRG Oncology is currently accepting applications for general and core committees.

Applications DUE October 25, 2026 | Read more & How to Apply

7. Join us for the next PSC “Discuss With Us” session!

The Protocol Support Committee’s “Discuss With Us” series provides nurses and clinical research associates with an opportunity to connect with colleagues, explore timely oncology topics, and strengthen their knowledge of clinical research and patient care. This interactive educational series is designed to provide practical, relevant information that can be applied to your work in oncology. Each session offers 1.25 continuing education contact hours through the Virginia Nurses Association.

Our next session will focus on:

Colorectal Cancer Essentials: A Clinical Refresher

📅 Wednesday, October 21, 2026 | 🕝 2:30 p.m. ET

Register once. Join us all year!

If you haven’t already registered, now is a great time to join the series. You only need to register once, and you will receive calendar invitations for all future “Discuss With Us” sessions, which are now scheduled through 2027.

Register today or scan the QR code to get started. Already registered? No action is needed. Just watch your calendar for the next session invitation!

Missed a session? Catch up anytime.

Visit the Discuss With Us page on the NRG Oncology website to access recordings, slide presentations, and information about upcoming sessions.

Add “Discuss With Us” to your monthly calendar and make the most of this ongoing educational opportunity!

8. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the scientific articles published during the previous week as well as abstracts accepted for presentation at upcoming conferences. Where available, this report includes links to the full article, PubMed abstract, or conference abstract.

TEMPLATE UPDATE

NRG Oncology has updated our branded presentation slides to be used when presenting NRG Oncology research or organizational activities. You can download the current version of our presentation slide template here on the NRG Oncology website.  

PUBLISHED ARTICLES

Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, Matuszak MM, Milano MT, Jaskowiak NT, Jagsi R, Kuhn P, Lucci A, Meas S, Shishido SN, Mason J, Bazan JG Jr, Nordal RA, Lee DY, Smith BD, Gabos Z, Ye JC, Kahn ST, Vallow LA, Zoberi I, Razaq W, Mishra MV, Lupinacci KM, Moughan J, Mamounas EP, White JR. NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer. J Clin Oncol. 2026 Oct 7:JCO2600201. doi: 10.1200/JCO-26-00201. Epub ahead of print. PMID: 42842849; PMCID: PMC13647293. Read more. Listen to our Podcast episode on this publication.

Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer. J Clin Oncol. 2026 Oct 10;44(29):2824-2834. doi: 10.1200/JCO-25-03052. Epub 2026 Jul 29. PMID: 42525921; PMCID: PMC13459625. Read more.

UPCOMING CONFERENCES & DEADLINES

This is an important season for abstract submissions, so it is essential to keep an eye on upcoming deadlines. Please send your drafts to NRG-Publications@NRGOncology.org as soon as possible so we can confirm all requirements are met before the deadline.

MEETINGS:

October 2026

• International Society for Quality-of-Life Research (ISOQOL) | Oct 18–21, 2026, Prague, Czech Republic
• European Society for Medical Oncology (ESMO) | Oct 23–27, 2026, Madrid, Spain

November 2026

• Society for Immunotherapy of Cancer | Nov 4–8, 2026, Phoenix, AZ
• Society for Neuro-Oncology (SNO) | Nov 12–15, Philadelphia, PA
• EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | Nov 18–20, 2026, Barcelona, Spain
• Radiological Society of North America (RSNA) | Nov 29–Dec 3, 2026, Chicago, IL

December 2026

• Society of Urologic Oncology (SUO) | Dec 1–4, 2026, Napa, CA
• ESMO Asia Congress |Dec 4–6, 2026 | Singapore
• San Antonio Breast Cancer Symposium (SABCS) | Dec 8–11, 2026, San Antonio, TX

2027

• ASCO Genitourinary Cancers Symposium (ASCO GU) | Feb 11–13, 2027, San Francisco, CA
• Society of Surgical Oncology – Advanced Cancer Therapies | Feb 13–15, 2027, Scottsdale, AZ
• American Head & Neck Society (AHNS) | Apr 7–11, 2027, Seattle, WA
• American Association for Thoracic Surgery (AATS) | May 1–4, 2027, Los Angeles, CA

ABSTRACT SUBMISSION DEADLINES:

October 2026

Mon, Oct 19 | EORTC-NCI-AACR Symposium on Molecular Targets & Cancer Therapeutics | Nov 18–20, 2026, Barcelona, Spain

▶ LBA: Oct 19, 24:00 CET

Mon, Oct 19 | Society of Urologic Oncology (this year, hosted by AUA 2027 Annual Meeting) | May 21–24, 2027, San Diego, CA

▶ Due to NRG Publications: Oct 19

Submission deadline: Nov 2, 12:00pm (noon) ET

Clinical Trials in Progress deadline: Jan 22, 2027, 12:00pm (noon) ET

Wed, Oct 21 | American Society of Breast Surgeons (ASBrS) | Apr 7–11, 2027, Orlando, FL

▶ Due to NRG Publications: Oct 21

Submission deadline: Nov 4, 11:59pm ET

LBA: Jan 20, 2027, 11:59pm ET

Thu, Oct 22 | ASCO Gastrointestinal Cancers Symposium (ASCO GI) | Jan 21–23, 2027, San Francisco, CA

▶ LBA: Oct 22, 12:00pm (noon) ET (LBA placeholder required)

Tue, Oct 27 | American Association for Cancer Research (AACR) | Apr 2–7, 2027, Washington, DC

▶ Due to NRG Publications: Oct 27

Submission deadline: Nov 10, 11:59pm ET

LBA (LBA and Clinical Trials): Jan 6, 2027, 11:59pm ET

Wed, Oct 28 | European Society for Radiotherapy and Oncology (ESTRO) | May 21–25, 2027, Milan, Italy

▶ Due to NRG Publications: Oct 28

Submission deadline: Nov 11, 23:59 CET

LBA: Mar 31, 2027, 23:59 CET

Fri, Oct 30 | European Society of Gynaecological Oncology (ESGO) | Feb 25–28, 2027, London, United Kingdom

▶ Submission deadline: Oct 30, 23:59 CET

LBA: Jan 15, 2027, 23:59 CET

November 2026

Tue, Nov 3 | American Surgical Association (ASA)| Apr 15–17, 2027, Houston, TX

▶ Due to NRG Publications: Nov 3

Submission deadline: Nov 17, 11:59pm ET

Thu, Nov 12 | ASCO Genitourinary Cancers Symposium (ASCO GU) | Feb 11–13, 2027, San Francisco, CA

▶ LBA: Nov 12, 12:00pm (noon) ET (LBA placeholder required)

Tue, Nov 17 | Society for Clinical Trials (SCT) | May 16–19, 2027, Chicago, IL

▶ Due to NRG Publications: Nov 17

Submission deadline: Dec 1

December 2026

Tue, Dec 1 | Society of Surgical Oncology (SSO) – Annual Meeting | Mar 18–20, 2027, Washington, DC

▶ LBA: Dec 1, 11:59pm CT (LBA placeholder required)

Tue, Dec 1 | St. Gallen Breast Cancer Conference (20th) | Mar 17–20, 2027, Vienna, Austria

▶ Due to NRG Publications: Dec 1

Submission deadline: Dec 15

January 2027

Tue, Jan 5 | Society of Gynecologic Oncology (SGO) | Mar 19–22, 2027, Phoenix, AZ

▶ LBA: Jan 5, 2027 (LBA placeholder required)

Tues, Jan 12 | American Society of Clinical Oncology (ASCO) | Jun 4–8, 2027, Chicago, IL

▶ Due to NRG Publications: Jan 19, 2027 (LBA placeholder required)

Submission deadline: Jan 26, 2027, 11:59pm ET

LBA: Mar 8, 2027, 11:59pm ET

Tue, Jan 19 | ESMO Breast | May 12–14, 2027, Milan, Italy

▶ Due to NRG Publications: Jan 19, 2027 (LBA placeholder required)

Submission deadline: Feb 2, 2027, 21:00 CET

LBA: Apr 6, 2027, 21:00 CET

Wed, Jan 27 | American Society of Colon and Rectal Surgeons (ASCRS) | May 22-25, 2027, New Orleans, LA

▶ LBA and Clinical Trials in Progress: Jan 27, 2027